Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of V114 versus Prevnar 13 in healthy infants
MOH_2017-02-23_000167Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine and Prevnar 13 in pneumococcal disease (3 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability of V114 versus Prevnar 13. Started Jan 2017; status: recruiting.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on MOH_2017-02-23_000167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-23_000167.